WCM
UTHR icon

Weld Capital Management’s United Therapeutics UTHR Stock Holding History

Weld Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,579
Closed -$675K – 667
2020
Q2 		$675K Sell
5,579
-13,871
-71% -$1.56M 0.26% 133
2020
Q1 		$1.84M Buy
+19,450
New +$1.85M 0.94% 6
2019
Q1 		– Sell
-2,137
Closed -$233K – 891
2018
Q4 		$233K Buy
+2,137
New +$248K 0.05% 560

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Weld Capital Management's UTHR Position: Q3 2020 in Review

Weld Capital Management sold out of United Therapeutics (UTHR) in Q3 2020, closing a stake of 5,579 shares — an estimated $675K sold.

Weld Capital Management first reported a position in UTHR in Q4 2018 and held it in 3 quarters. The position peaked at $1.84M in Q1 2020. 332 funds tracked by Wall St. Rank hold UTHR as of Q3 2020.

  • Weld Capital Management reported no remaining United Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Weld Capital Management sold 5,579 United Therapeutics shares in Q3 2020, an estimated $675K.
  • Weld Capital Management first reported a position in United Therapeutics in Q4 2018 and held it in 3 quarters.
  • Weld Capital Management's United Therapeutics position peaked at $1.84M in Q1 2020.
  • 332 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2020.

Based on Weld Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.